Dr. Aaron Rosenberg
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
12 reported clinical trials
21 drugs studied
Area of expertise
1Multiple Myeloma
TP53 positive
TP53 negative
Tetrasomies positive
2Plasma Cell Neoplasms
Affiliated Hospitals
Clinical Trials Aaron Rosenberg is currently running
Iberdomide
for Multiple Myeloma
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
Recruiting1 award Phase 210 criteria
Selinexor Combination Therapy
for Multiple Myeloma
This phase II trial compares the combination of selinexor, daratumumab and hyaluronidase-fihj (daratumumab), velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-risk newly diagnosed multiple myeloma. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The drugs daratumumab, lenalidomide, bortezomib, dexamethasone and selinexor are already approved by the Food and Drug Administration for use in myeloma. But selinexor is not used until myeloma comes back (relapses) after initial treatment. Giving selinexor in the initial treatment may be a superior type of treatment for patients with high-risk newly diagnosed multiple myeloma.
Recruiting1 award Phase 2
More about Aaron Rosenberg
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Aaron Rosenberg has experience with
- Lenalidomide
- Dexamethasone
- Idecabtagene Vicleucel
- Fludarabine
- Cyclophosphamide
- Daratumumab And Hyaluronidase-fihj
Breakdown of trials Aaron Rosenberg has run
Multiple Myeloma
Plasma Cell Neoplasms
Hematologic Malignancies
Blood Cancers
Plasmacytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aaron Rosenberg specialize in?
Aaron Rosenberg focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved TP53 positive patients, or patients who are TP53 negative.
Is Aaron Rosenberg currently recruiting for clinical trials?
Yes, Aaron Rosenberg is currently recruiting for 4 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Aaron Rosenberg has studied deeply?
Yes, Aaron Rosenberg has studied treatments such as Lenalidomide, Dexamethasone, Idecabtagene Vicleucel.
What is the best way to schedule an appointment with Aaron Rosenberg?
Apply for one of the trials that Aaron Rosenberg is conducting.
What is the office address of Aaron Rosenberg?
The office of Aaron Rosenberg is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.